PIK3CG and neoplasm: More specifically, the PI3Kα-specific or pan-PI3K inhibitor did not show an anti-tumor response over ICI alone in TNBC models, while the PI3K/mTOR dual inhibitor gedatolisib associated with ICIs induced a substantial cancer growth inhibition and a greater activation and response of T-cells, natural killer (NK)-cell, and dendritic cells (DC) [153].